EGFR and cancer: A novel monoclonal antibody (mAb) known as D2C7 reacts with both the wild-type epidermal growth factor receptor and (EGFRvIII) (both of which are major glioblastoma driver oncogenes) overexpressed on the surface of cancer cells.